Hypercalcemia Treatment Market Report 2026

Hypercalcemia Treatment Market Overview

• Hypercalcemia Treatment market size has reached to $18.29 billion in 2025 • Expected to grow to $31.12 billion in 2030 at a compound annual growth rate (CAGR) of 11.2% • Growth Driver: Rising Prevalence Of Parathyroid Disorders Driving Growth In The Market • Market Trend: Advanced Hypercalcemia Treatment With Innovative Phosphate Binders • North America was the largest region in 2025.

What Is Covered Under Hypercalcemia Treatment Market?

Hypercalcemia treatment is the medical management of elevated calcium levels in the blood resulting from conditions such as hyperparathyroidism or malignancies. Treatment includes hydration, diuretics, bisphosphonates, or calcitonin to lower calcium levels and prevent complications. It is applied in emergency and long-term care settings to prevent kidney damage, neurological issues, and cardiac dysfunction. The main drug types of hypercalcemia treatment are bisphosphonates, calcitonin, glucocorticoids, denosumab, calcimimetics, and others. Bisphosphonates are a class of medications used to treat bone diseases by inhibiting the activity of osteoclasts, the cells responsible for breaking down bone tissue. The various indications include primary hyperthyroidism, hypercalcemia of malignancy, and others. They are distributed through multiple channels, such as hospitals, pharmacies, retail pharmacies, and online pharmacies, and are used by several end-users, including hospitals and clinics.

What Is The Hypercalcemia Treatment Market Growth Forecast?

The hypercalcemia treatment market size is expected to see rapid growth in the next few years. It will grow to $31.12 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to growing cancer patient population, increased adoption of denosumab therapy, advancements in calcimimetic drugs, rising awareness of early diagnosis, expansion of outpatient and long-term care management. Major trends in the forecast period include increasing use of targeted therapies for hypercalcemia, growing preference for rapid-acting injectable treatments, rising focus on oncology-associated hypercalcemia management, expansion of combination drug therapies, greater adoption of protocol-based emergency management.

Global Hypercalcemia Treatment Market Segmentation

1) By Drug Type: Bisphosphonates, Calcitonin, Glucocorticoids, Denosumab, Calcimimetics, Other Drug Types 2) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End-Users: Hospitals, Clinics Subsegments: 1) By Bisphosphonates: Zoledronic Acid, Pamidronate 2) By Calcitonin: Salmon Calcitonin, Synthetic Calcitonin 3) By Glucocorticoids: Prednisone, Dexamethasone, Hydrocortisone 4) By Denosumab: Denosumab (Monotherapy), Denosumab Combination Therapy 5) By Calcimimetics: Cinacalcet, Etelcalcetide 6) By Other Drug Types: Gallium Nitrate, Mithramycin

What Is The Driver Of The Hypercalcemia Treatment Market?

The rise in the prevalence of parathyroid disorders is expected to propel the growth of the hypercalcemia treatment market going forward. Parathyroid disorders refer to conditions affecting the parathyroid glands, which regulate calcium levels in the body through the production of parathyroid hormone (PTH). The rising prevalence of parathyroid disorders is driven by an aging population, increased awareness, improved diagnostic capabilities, and a growing incidence of conditions such as primary hyperparathyroidism and chronic kidney disease. Hypercalcemia treatment is crucial in managing parathyroid disorders by regulating elevated calcium levels, preventing complications like kidney stones and bone loss, and improving overall metabolic balance. For instance, in February 2024, according to the National Institute of Health (NIH), a US-based government agency, in the United States, hypoparathyroidism is estimated to affect 6.4 to 37 per 100,000 person-years, with 75% of cases resulting from complications of thyroidectomy or head and neck surgery. Therefore, the rise in the prevalence of parathyroid disorders is driving the growth of the hypercalcemia treatment industry.

Key Players In The Global Hypercalcemia Treatment Market

Major companies operating in the hypercalcemia treatment market are Amgen Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Merck KGaA, Eli Lilly and Company, AstraZeneca plc, GSK plc, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Ipsen SA, Endo Inc., OPKO Health Inc., Sanofi, Bayer AG, Sun Pharmaceutical Industries Ltd., Dr Reddy's Laboratories Ltd., Aurobindo Pharma Ltd.

Global Hypercalcemia Treatment Market Trends and Insights

Major companies operating in the hypercalcemia treatment market are focusing on developing innovative products, such as phosphate binders, to regulate calcium and phosphorus balance better, improving treatment outcomes. Phosphate binders are medications that bind to phosphate in the digestive tract, preventing its absorption into the bloodstream, and are commonly used to manage high phosphate levels in patients with kidney disease or hypercalcemia. For instance, in May 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, received approval from the United States Food and Drug Administration (FDA) for its Sevelamer Carbonate Tablets, 800 mg. These effectively manage hyperphosphatemia in patients with chronic kidney disease by binding dietary phosphate and preventing its absorption. These tablets help maintain bone health and reduce cardiovascular risks associated with elevated phosphate levels.

What Are Latest Mergers And Acquisitions In The Hypercalcemia Treatment Market?

In December 2024, Teijin Pharma Limited, a Japan-based pharmaceutical company, partnered with Ascendis Pharma A/S. The partnership allows Teijin to leverage innovative prodrug technology that provides sustained PTH levels, potentially offering a more effective and convenient treatment option than existing therapies. Ascendis Pharma A/S is a Denmark-based company that specializes in developing innovative prodrugs for treating hypoparathyroidism in adults.

Regional Outlook

North America was the largest region in the hypercalcemia treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hypercalcemia Treatment Market?

The hypercalcemia treatment market consists of revenues earned by entities through services such as surgical treatment, dietary modifications, and bisphosphonates. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypercalcemia treatment market also includes sales of metabolic testing devices, body composition analyzers, and wearable fitness trackers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hypercalcemia Treatment Market Report 2026?

The hypercalcemia treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hypercalcemia treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.